-
Germans vote in elections threatening fresh blow to Merz
-
Russians vote on last day of parliamentary elections
-
US fears rapid escalation in Mideast after Houthis attack Riyadh
-
Hong Kong pays final respects to former city leader Tung
-
Japan triathlete Hojo wins first gold of Asian Games
-
Typhoon put people off Asian Games opening ceremony, official says
-
IOC president impressed by 'beautiful' Asian Games wooden huts
-
China's 13-year-old Yu cruises as Asian Games swimming begins
-
First Asian Games gold goes to Japan as China's 13-year-old Yu lights up pool
-
AI 'warning shots' focus Beijing on national security risks
-
Data centre command hub keeps AI up and running
-
Philippine tribe in limbo over US-led tech hub
-
Pope Leo in France: the issues on the table
-
Leo XIV, first US pope transcends his restrained style
-
Packing for a pope: behind the scenes on foreign trips
-
Singer Ed Sheeran says Gaza situation 'unjustifiable' following controversy
-
Republicans find transgender issues a powerful political weapon in midterm campaigning
-
In 'Tenzing', a Sherpa mountaineer gets his due
-
German state elections threaten new shock waves for Merz
-
Ed Sheeran set to return to stage after Palestinian controversy
-
Chile's Bachelet quits race to be next UN chief
-
Toulouse edge Vannes, Lyon beat Pau to take Top 14 summit
-
Raphinha treble fires perfect Barca to win at Sevilla
-
Germans arrested for Louvre stunt in Mona Lisa hall
-
Thiam makes winning heptathlon return at Decastar meet
-
Saudi-led coalition says Houthis fired ballistic missile at Riyadh
-
Czechs beat USA to qualify for Davis Cup finals
-
France's debt climbs to highest since 1978: ministry
-
Dortmund sink Stuttgart to climb to Bundesliga summit
-
McIlroy two shots off the lead at Wentworth after eagle on 18
-
Trump says will not tolerate attempts to slow AI growth
-
Martinez brace saves Inter in Serie A top-two clash with Roma
-
'It has to stop': runners protest women's murders in S.Africa district
-
Rosenior abused but guides Paris FC past old club Strasbourg
-
Fire erupts near Riyadh airport as Houthis claim strikes
-
Seven-try Lyon beat Pau, climb to Top 14 summit
-
Cuba works to restore power after another blackout
-
Brighton defeat a 'big lesson' against complacency for Arsenal, says Arteta
-
England thrash Sri Lanka again to return to top of T20 rankings
-
Thousands protest inaction over climate crisis in Switzerland
-
Arsenal thrashed by Brighton, sorry Spurs lose again
-
Carapaz out of cycling world championships
-
South Korea, Austria qualify for Davis Cup finals
-
'Fragile' Tottenham beaten by Aston Villa despite late rally
-
Seare shocks Ingebrigtsen to win world 5km gold
-
Mourinho hails Real Madrid grit before Atletico derby clash
-
Brigitte Bardot widower slams sale of star's belongings
-
Martin wins Austrian MotoGP sprint after Acosta crash
-
Aston Villa compound Tottenham's misery despite late rally
-
Japan edge Fiji to win Pacific Nations Cup
Canada health authority approves Pfizer's anti-Covid pill
Canada's health authority said Monday it has approved Pfizer's anti-Covid pill, Paxlovid, for adults at high risk of progressing to serious disease.
The oral treatment was approved after an "expedited review," Health Canada said in a statement on its website, adding that it would continue to monitor its safety and effectiveness.
"No drug, including PAXLOVID TM, is a substitute for vaccination," the statement added.
The drug, which comprises two types of tablet, is the first Covid-19 therapy which can be taken at home, and is potentially a huge step towards ending the pandemic.
"Today's announcement is particularly important as access to easy-to-use treatments could help to reduce the severity of Covid-19 in adults who become newly infected and are at high-risk of progressing to serious illness," said Theresa Tam, Canada's chief public health officer.
The approval comes as Canada, like many countries, has been struggling to contain the Omicron variant of Covid-19.
The French-speaking province of Quebec recently announced it would levy a tax on the unvaccinated, arguing they impose a burden on everyone else.
Paxlovid has so far been authorized in a handful of countries including the United States and Israel, while the European Union has allowed member states to use it ahead of formal approval as an emergency measure against Omicron.
Unlike vaccines, it does not target the ever-evolving spike protein which the coronavirus uses to invade cells.
It should therefore in theory be more variant-proof, and the company has said preliminary lab studies have backed up that hypothesis.
Nogueira--PC